Search results
Showing 256 to 270 of 690 results for innovative
NICE Advice is an advisory service for pharmaceutical and healthtech companies seeking to enter the NHS market, and supporting organisations who fund or generate evidence for health technologies.
NICE has developed a medtech innovation briefing (MIB) on Optilume for anterior urethral strictures .
NICE has developed a medtech innovation briefing (MIB) on Granulox for managing chronic non-healing wounds .
Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment (TA1001)
Evidence-based recommendations on zanubrutinib (Brukinsa) for marginal zone lymphoma after anti-CD20-based treatment in adults.
Evidence-based recommendations on nivolumab (Opdivo) with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer in adults.
Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)
Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults.
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)
Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Lennox–Gastaut syndrome in people aged 2 years and older.
Maribavir for treating refractory cytomegalovirus infection after transplant (TA860)
Evidence-based recommendations on maribavir (Livtencity) for cytomegalovirus infection in adults after transplant.
NICE has developed a medtech innovation briefing (MIB) on narrow band imaging for Barrett’s oesophagus .
myAIRVO2 for the treatment of chronic obstructive pulmonary disease (MIB161)
NICE has developed a medtech innovation briefing (MIB) on myAIRVO2 for the treatment of chronic obstructive pulmonary disease .
NICE has developed a medtech innovation briefing (MIB) on ADXBLADDER for detecting bladder cancer .
Magseed for locating impalpable breast cancer lesions (MIB236)
NICE has developed a medtech innovation briefing (MIB) on Magseed for locating impalpable breast cancer lesions .
Evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults.
Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)
Evidence-based recommendations on larotrectinib (Vitrakvi) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children.
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria (TA778)
Evidence-based recommendations on pegcetacoplan (Aspaveli) for treating paroxysmal nocturnal haemoglobinuria in adults who have anaemia after at least 3 months of treatment with a C5 inhibitor.